Nov 2019
ANTG CRAFTS A PATHWAY TO PROFIT
What’s most important in business – purpose or profit? At ANTG we get to achieve both. Our revenue streams build business sustainability, allowing us to continue to focus on our passion for the plant and the people it can help. Our CEO, Matt Cantelo lays out our pathway to profits. Read the article here.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We’re pleased to announce we have successfully passed the TGO93 and TGO100 mandatory tests for our first commercial export crop.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.
LEARN ABOUT ANTG HERE >